Clovis Oncology, Inc.

OTCPK:CLVS.Q 주식 리포트

시가총액: US$2.2m

Clovis Oncology 경영진

경영진 기준 점검 3/4

Clovis Oncology CEO는 Patrick Mahaffy, Apr2009 에 임명되었습니다 의 임기는 14.25 년입니다. 는 $14.56K 가치에 해당하는 회사 주식의 0.67% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 각각 7.4 년과 14.3 년입니다.

핵심 정보

Patrick Mahaffy

최고경영자

n/a

총 보수

CEO 급여 비율n/a
CEO 재임 기간14.3yrs
CEO 지분 보유율0.7%
경영진 평균 재임 기간7.4yrs
이사회 평균 재임 기간14.3yrs

최근 경영진 업데이트

분석 기사 • Jun 17

Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Shareholders of Clovis Oncology, Inc. ( NASDAQ:CLVS ) will have been dismayed by the negative share price return over...
분석 기사 • Mar 17

Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

Investors may wish to note that an insider of Clovis Oncology, Inc. , Thomas Harding, recently netted US$56k from...

Recent updates

Seeking Alpha • Sep 21

Clovis Oncology rises on clinical supply agreement with Isotopia

Clovis Oncology (NASDAQ:CLVS) said on Wednesday it had signed a clinical supply agreement that would provide it with Isotopia’s lutetium-177 n.c.a. for use in the development of FAP-2286, fibroblast activation protein, that targets therapeutic candidate. (CLVS) has risen 4.5% before the bell. FAP-2286 is currently being developed in the Phase 1/2 study to treat patients with advanced solid tumors. The agreement covers an initial period of two years. "Over the past four years, Isotopia has strengthened its supply chain to support the growing global demand and need for higher supply security," said Keren Moshkoviz, Deputy CEO and BD at Isotopia. FAP is highly expressed by cancer-associated fibroblasts (CAFs) which are found in the majority of cancer types, but with limited expression in healthy fibroblasts, potentially making it a suitable target across a wide range of tumors.
Seeking Alpha • Sep 12

Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial

Clovis Oncology (NASDAQ:CLVS) said Rubraca as initial maintenance therapy improved progression-free survival (PFS), compared to placebo across disease risk subgroups in patients with ovarian cancer. The company presented data from a subgroup analysis of a monotherapy comparison in the phase 3 trial called ATHENA at the European Society of Medical Oncology (ESMO) Congress 2022 in Paris. ATHENA-MONO enrolled 538 women with high-grade ovarian, fallopian tube or primary peritoneal cancer. Patients who received Rubraca as maintenance therapy showed PFS (length of time during/after therapy a patient lives with the disease without it getting worse) benefit regardless of surgical outcome, whether there was complete resection during cytoreductive surgery or not, the company said in a Sept. 11 press release. In addition, patients treated with Rubraca as maintenance therapy showed benefit among all subgroups when evaluated against response per RECIST v1.1 at any time during first-line chemotherapy. Clovis noted that in other subgroups based on baseline clinical characteristics, including FIGO stage, timing of surgery, and CA-125 levels, also showed that patients treated with Rubraca experienced a PFS benefit compared to those treated with placebo. CLVS +14.78% to $1.32 premarket Sept. 12
Seeking Alpha • Aug 11

Clovis Oncology: Needs Some Encouraging Data Quickly

Funding difficulties have definitely been priced into Clovis' share price. Clovis, though, has some interesting readouts due this year and in early 2023. If data is encouraging and new funding is announced, CLVS stock could rally sharply from present levels. Intro If we look at a long-term chart of Clovis Oncology, Inc. (CLVS) (Antin Cancer Biotech Company), we see that shares topped out in 2017 and have been making sustained lower lows ever since. Suffice it to say, a lot of shareholders have been burned by this play, and if the present bearish trend continues, shares could easily test the stock's year-to-date lows of well under $1 a share. If indeed though shares swoop down to their 2022 lows in the not too distant future, the risk/reward play would be heavily skewed to the upside because of what the company still has in its locker in our opinion. Clovis Technical Chart (Stockcharts.com) Clovis Needs Capital Suffice it to say, it then would boil down to how much the company's assets are worth to a partner if indeed a third party is to enter the scene here, which now looks highly likely. Management announced on its recent quarterly earnings call that raising capital through public or private equity means is not an option at present due to the recent unsuccessful stock split. So, Clovis' current options with respect to facilitating funding seem to be to either increase the number of shares or enter into some type of licensing agreement. The reason being is that when forward-looking revenue projections and the company´s current cash-burn rate are taken into account, operations will eventually come to a grinding halt in early 2023 if no new funding is found. Rubraca Sales Are Not Growing Unfortunately, Rubraca has not performed up to expectations. This means Clovis' pipeline has literally run out of time. Rubraca sales came in at $32.1 million in the company's fiscal second quarter, which was a 6% sequential decline as well as a 13% decrease compared to the same period of 12 months prior. Covid-19 has been a clear headwind here due to fewer numbers of people going through the system. This has led to a fall-off in second-line maintenance treatment. Furthermore, recent insider selling demonstrates management's outlook on how Rubraca is expected to fare going forward, which obviously has been factored in as to when the firm will run out of money. Pipeline However, with respect to the pipeline, management was quick to point to the ongoing FAP-2286 (Lead candidate in Radionuclide therapy) LuMiere trial with respect to its recent encouraging results. When we take into account the tumor space, which is a significant area of high unmet need, along with recent evidence regarding Fap-2286's sound safety and clinical implications, this will be a trial that will be watched very closely going forward by all cohorts in this space. Then, on the Rubraca side, the ongoing TRITON3 & ATHENA studies offer the opportunity to bring to the market earlier therapy solutions for prostate and ovarian cancer patients. Regarding ovarian cancer, Clovis has plenty of indications in late stages in ATHENA-MONO & ATHENA-COMBO, where we should have updated information in this space in the latter stages of this fiscal year as well as early next year. Remember, the goal here is to widen the net so to speak with respect to patients undergoing therapy in this space. The same goes for specific prostate cancer patients in the TRITON3 trial where we should have an update over the next few months or so. Worrying Financials The question then becomes how much is this pipeline worth, notwithstanding Rubraca's U.S. and international product revenues. Remember, Clovis has well over $600 million of long-term debt on its balance sheet and continues to report negative shareholder equity. Suffice it to say, its bargaining position is not healthy, as the company will most likely have to give up more than it wishes to attract the interests of a funded third party.
분석 기사 • Aug 10

These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat

Today is shaping up negative for Clovis Oncology, Inc. ( NASDAQ:CLVS ) shareholders, with the analysts delivering a...
Seeking Alpha • Aug 05

Clovis Oncology Q2 2022 Earnings Preview

Clovis Oncology (NASDAQ:CLVS) is scheduled to announce Q2 earnings results on Monday, August 8th, before market open. The consensus EPS Estimate is -$0.43 (+29.5% Y/Y) and the consensus Revenue Estimate is $37.08M (+0.7% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 3 downward.
Seeking Alpha • Jul 22

EMA recommends restricted use of Clovis cancer drug

The European Medicines Agency (EMA) announced on Friday Rubraca (rucaparib camsylate), a cancer medication marketed by the U.S. biotech Clovis Oncology (NASDAQ:CLVS) should no longer be used as a third line treatment for certain cancers due to concerns over safety/quality. Per the recommendation of the EMA’s Committee for Medicinal Products for Human Use (CHMP), the drug, also known as rucaparib camsylate will not be indicated as a third line option for certain patients with cancers in the ovary, fallopian tubes or peritoneum with a BRCA mutation. A review on the quality, safety and efficacy issues of the treatment led to the decision, the EMA added.  In 2018, the EU regulators granted conditional marketing authorization for Rubraca as a third line option for certain patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Previously, the oral small molecule inhibitor was authorized in Europe for certain patients in the recurrent ovarian cancer maintenance setting regardless of their BRCA mutation status.
Seeking Alpha • Jul 08

Clovis Oncology climbs 34% as shareholders reject reverse stock split

Clovis Oncology (NASDAQ:CLVS), a biotech focused anti-cancer agents, added more than 34% to reach the highest level since April after the company’s shareholders rejected a proposal to implement a reverse stock split. Disclosing the outcome of its 2022 stockholder meeting, Clovis (CLVS) said that the shareholders did not approve two proposals: the 1-for-7 reverse stock split and a concurrent plan to decrease the number of authorized shares of common stock. The company had previously adjourned its annual meeting to discuss three proposals. However, shareholders have greenlighted only one proposal related to a stock incentive plan when the meeting was resumed yesterday.   Despite more than a threefold rise over the past 30 days, Clovis (CLVS) shares remain ~45% lower than the year-ago level, as shown in this graph.
Seeking Alpha • Apr 25

Clovis: Shifting Toward Nuclear Medicine

Clovis, a "trading stock," has some shakiness in its fundamentals. Moreover, the shares tend to rise and fall for you to trade for short-term gains. Due to upcoming catalysts in June, Clovis is a trading stock that is about to embark on another bullish cycle. Despite being a trading stock, Clovis shares are still changing hands at a deep valuation to their true value.
Seeking Alpha • Mar 31

Clovis Oncology: Forging A Fresh Perspective

Clovis Oncology recently reported impressive data from their ATHENA-MONO Phase III study. The ATHENA-MONO data should support the use of Rubraca in the first-line ovarian setting. The company is scheduled to report data from two more Phase III studies for Rubraca this year. Clovis has a chance to be a leader in targeted radionuclide therapies. FAP-2286 is the company's lead FAP program and will be the first TRT to enter the clinic. It is time to take on a fresh perspective. The company’s recent earnings report and company updates hold key materials required to forge a new thesis for CLVS. CLVS is now trading up on the ATHENA-MONO news and is starting to break long-term downtrends on both the Monthly and Daily charts.
분석 기사 • Feb 24

News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat

One thing we could say about the analysts on Clovis Oncology, Inc. ( NASDAQ:CLVS ) - they aren't optimistic, having...
Seeking Alpha • Jan 11

Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts

The stock is significantly undervalued and this year could unlock significant near-term value in the form of ATHENA trial data. Long-term (3-4 years) first price target = $40 (15x potential). Blue sky (5 years) price target = $88 (32x potential). The article provides the target markets and calculations behind the price targets.
Seeking Alpha • Dec 30

Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward

Clovis Oncology has had a rough 2021, with Rubraca sales continuing to disappoint. The company’s Q3 sales revealed a slight increase quarter-over-quarter and a slight decrease year-over-year. The company points to COVID-19 headwinds and a decrease in the number of new ovarian cancer diagnoses. I am leaning more towards the lackluster demand for PARP inhibitors. The company is promoting their FAP efforts, which can keep CLVS in play in the coming years. Targeted radionuclide therapies could reignite the CLVS buyout chatter. 2022 could be a pivotal year for Clovis and its share price. The company has several potent milestones that could provide opportunities to manage a position. The prolonged sell-off has knocked the premium right out of CLVS. I believe the ticker is now discounted and offers a great risk-reward for speculative investment.
Seeking Alpha • Oct 07

Clovis Oncology Stock: Only Glimmers Of Hope

Today, we revisit Clovis Oncology for the first time in many years. The company has destroyed tons of shareholder value in that time as the PARP inhibitor space has been very disappointing to date. Can the company and stock rebound? We attempt to answer that question in the investment analysis below.
Seeking Alpha • Jul 30

Clovis: Compelling With Upcoming Catalysts

After a 25% selloff in the last 6 weeks, Clovis presents a compelling risk/reward ratio with upcoming catalysts in the next 3 months. Athena data is due in September which could move Rubraca into the largest oncology market in its class and make it a potential blockbuster. Targeted radiotherapy is the future of cancer treatment and Clovis is a pioneer in this area with its FAP pipeline. Earnings on August 4 will provide much-needed clarity from management.
분석 기사 • Jun 17

Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Shareholders of Clovis Oncology, Inc. ( NASDAQ:CLVS ) will have been dismayed by the negative share price return over...
분석 기사 • Mar 17

Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

Investors may wish to note that an insider of Clovis Oncology, Inc. , Thomas Harding, recently netted US$56k from...
분석 기사 • Feb 22

How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?

It is doubtless a positive to see that the Clovis Oncology, Inc. ( NASDAQ:CLVS ) share price has gained some 59% in the...
분석 기사 • Dec 31

What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?

Every investor in Clovis Oncology, Inc. ( NASDAQ:CLVS ) should be aware of the most powerful shareholder groups. Large...

CEO 보수 분석

Patrick Mahaffy의 보수는 Clovis Oncology의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Sep 30 2022n/an/a

-US$252m

Jun 30 2022n/an/a

-US$263m

Mar 31 2022n/an/a

-US$258m

Dec 31 2021US$3mUS$739k

-US$265m

Sep 30 2021n/an/a

-US$299m

Jun 30 2021n/an/a

-US$310m

Mar 31 2021n/an/a

-US$336m

Dec 31 2020US$3mUS$721k

-US$369m

Sep 30 2020n/an/a

-US$370m

Jun 30 2020n/an/a

-US$385m

Mar 31 2020n/an/a

-US$413m

Dec 31 2019US$7mUS$719k

-US$400m

Sep 30 2019n/an/a

-US$400m

Jun 30 2019n/an/a

-US$396m

Mar 31 2019n/an/a

-US$377m

Dec 31 2018US$6mUS$689k

-US$368m

Sep 30 2018n/an/a

-US$321m

Jun 30 2018n/an/a

-US$291m

Mar 31 2018n/an/a

-US$366m

Dec 31 2017US$9mUS$636k

-US$346m

Sep 30 2017n/an/a

-US$365m

Jun 30 2017n/an/a

-US$370m

Mar 31 2017n/an/a

-US$324m

Dec 31 2016US$789kUS$224k

-US$349m

보상 대 시장: US 시장에서 비슷한 규모 기업과 비교해 Patrick의 총 보수가 적절한지 판단하기에 데이터가 부족합니다.

보상과 수익: Patrick의 보상은 지난 1년 동안 회사 실적과 일치했습니다.

CEO

Patrick Mahaffy (60 yo)

14.3yrs
재임 기간
US$2,639,083
보수

Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. in April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic...

리더십 팀

이름직위재임 기간보수지분
Patrick Mahaffy
Co-Founder14.3yrsUS$2.64m0.67%
$ 14.6k
Daniel Muehl
Executive VP & CFO7.3yrsUS$1.19m0.072%
$ 1.6k
Paul Gross
Executive VP7.5yrsUS$1.20m0.068%
$ 1.5k
Lindsey Rolfe
Executive VP of Clinical Development & Pharmacovigilance and Chief Medical Officer7.9yrsUS$1.24m0.078%
$ 1.7k
Thomas Harding
Executive VP & Chief Scientific Officer3.8yrs데이터 없음데이터 없음
Ann Bozeman
Executive Vice President of Human Resources6.8yrs데이터 없음데이터 없음
7.4yrs
평균 재임 기간
58yo
평균 나이

경험이 풍부한 관리: CLVS.Q의 경영진은 노련하고 경험이 풍부합니다(평균 재임 7.4 년).

이사회 구성원

이름직위재임 기간보수지분
Patrick Mahaffy
Co-Founder14.3yrsUS$2.64m0.67%
$ 14.6k
Paul Klingenstein
Independent Director14.3yrsUS$260.00k0.041%
$ 889.9
Brian Atwood
Independent Director14.5yrsUS$270.00k0.040%
$ 875.1
Edward McKinley
Independent Director14.5yrsUS$270.00k0.17%
$ 3.8k
James Blair
Independent Director14.5yrsUS$270.00k0.044%
$ 953.2
Ginger Graham
Independent Chairman10.5yrsUS$287.50k0%
$ 0
Thorlef Spickschen
Independent Director14.5yrsUS$257.50k0.040%
$ 872.7
Ronit Simantov
Director2yrsUS$375.21k데이터 없음
Keith Flaherty
Independent Director10.5yrsUS$259.58k0%
$ 0
Richard Fair
Independent Director4.8yrsUS$257.50k0%
$ 0
Robert Azelby
Independent Director4.8yrsUS$255.00k0%
$ 0
14.3yrs
평균 재임 기간
67yo
평균 나이

경험이 풍부한 이사회: CLVS.Q의 이사회는 노련하고 경험이 풍부합니다(평균 재임 14.3 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2023/07/12 23:29
종가2023/07/10 00:00
수익2022/09/30
연간 수익2021/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Clovis Oncology, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Tazeen AhmadBofA Global Research
Debjit ChattopadhyayBrean Capital Historical (Janney Montgomery)
Douglas BuchananBrean Capital Historical (Janney Montgomery)